Updates on Immune Checkpoint Inhibitors and Implications for Managed Care and Specialty Pharmacists

Updates on Immune Checkpoint Inhibitors and Implications for Managed Care and Specialty Pharmacists is organized by Power-Pak C.E. - Continuing Education for Pharmacists & Pharmacy Technicians.

Published Date: December 20, 2019
Expiration Date: December 20, 2020

Credits: 1.5 hour (0.15 ceu)

Goal:
This educational activity is designed to provide managed care and specialty pharmacists with updated knowledge of the evolving use of immune checkpoint inhibitors and how to optimally manage patients receiving these agents, thus leading to improved patient outcomes.

Educational Objectives:
Upon completion of this activity, the participant should be able to:
• Discuss the use of checkpoint inhibitor and checkpoint inhibitor combination regimens in patients with cancer, including indications and efficacy
• Examine the emerging checkpoint inhibitor and checkpoint inhibitor combination regimens being evaluated in clinical trials for the treatment of cancer and how to be poised for incorporation for formulary and clinical pathway development
• Identify appropriate prognostic and predictive biomarkers in the treatment of cancer with checkpoint inhibitors alone or in combination regimens
• Demonstrate pharmacist-driven strategies to recognize and effectively prevent or manage toxicities of checkpoint inhibitor and checkpoint inhibitor combination therapies

Additional details will be posted as soon as information is available.